IPBF: who are we ?

site map  
interstitial cystitis &
bladder pain syndrome (IC/BPS)
Hunner lesion  
hypersensitive bladder  
other pelvic pain conditions  
overactive bladder syndrome  
associated disorders  
the urinary tract: how it works  
news & reviews  
literature: selected topics  
IPBF newsletters  
IPBF publications  
information in other languages  
glossary of terms: A-Z  
information for professionals  
books, videos, CDs  
how to start and run a support group  
global IC/BPS support groups, contact persons and related organizations  
donations & sponsoring  
useful links  
disclaimer & copyright  


selected literature on oral treatment of PBS/IC    
click on the title to jump to the abstract if available
double-blind randomized placebo-controlled studies
  • Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
    Kay G, Crook T, Rekeda L, et al. Eur Urol 2006;50:317-26
    • Oxybutynin is used not only by OAB patients but also by many PBS/IC patients. This study concludes that oxybutynin ER caused significant memory deterioration (magnitude of effect comparable to brain aging of 10 years). The results also demonstrate that subjects may not recognise/report memory deterioration and memory decline may be attributed wrongly to aging. The findings highlight a need for further studies to fully establish the effects of all OAB antimuscarinics on memory/cognition.

    Antimuscarinics and cognitive function.
    De Ridder D.  Eur Urol 2006;50:211-2
    • in this editorial, the author adds that in many countries, for financial reasons, the older and cheaper oxybutynin will still be the treatment of choice
  • Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis.
    Warren JW, Horne LM, Hebel JR, et al. J Urol 2000;163:1685-8
    • 50 patients with IC were randomized to receive 18 weeks of placebo or antibiotics, including rifampin plus a sequence of doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin and ciprofloxacin for 3 weeks each.
    • 12 of 25 patients (48%) in the antibiotic and 6 of 25 (24%) in the placebo group reported overall improvement (p = 0.14), while 10 and 5, respectively, noticed improvement in pain and urgency (p = 0.22).
    • in the antibiotic group 20 participants (80%) had adverse effects compared with 10 (40%) in the placebo group (p = 0.009).
    • the authors conclude that their findings suggest that these antibiotics alone or in combination may sometimes be associated with decreased symptoms in some patients but they do not represent a major advance in therapy for interstitial cystitis
  • A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease.
    Holm-Bentzen M, Jacobsen F, Nerstrom B, et al. J Urol 1987;138:503-7
    • protocol A included 43 patients with clinically and pathologically anatomically verified interstitial cystitis (28 or more mast cells per mm.2)
    • protocol B included 72 patients with a painful bladder and unspecific histological findings
    • patients were randomized to receive either sodium pentosanpolysulfate (200 mg. twice daily) or placebo capsules for 4 months
    • before and after the trial the patients were evaluated with symptom grading, urodynamics and cystoscopy with distension and deep bladder biopsies
    • the results showed no difference between the pre-trial and post-trial values in the sodium pentosanpolysulfate and placebo groups in both protocols in regard to symptoms, urodynamic parameters, cystoscopic appearance and mast cell counts.
    • a significant increase in the cystoscopically determined bladder capacity in the sodium pentosanpolysulfate group in protocol A was found
    • the authors conclude that no statistically or clinically significant effect of sodium pentosanpolysulfate was found compared to placebo in patients with painful bladder disease
open studies and non-placebo-controlled studies
case reports
  • Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review.
    Dimitrakov J, Kroenke K, Steer WD, et al. Arch Intern Med 2007;167:1922-9.
    • over 180 different therapies have been tried for PBS/IC, yet evidence from trials remains inconclusive
    • this study concludes that PPS may be modestly beneficial for PBS/IC
    • there is insufficient evidence for other pharmacologic treatment
    • a consensus on standardized outcome measures is urgently needed
  • Efficacy of interstitial cystitis treatments: a review.
    Karsenty G, AlTaweel W, Hajebrahimi S, Corcos J. EAU-EBU Update Series 2006;4:47-61
    • in this article, the degree of evidence regarding the clinical efficacy of available interstitial cystitis treatment options is reviewed
    • only three therapies are supported by a high level of evidence: oral cimetidine and amitriptyline and the intravesical dimethylsulfoxide (DMSO)
  • Chondroitin sulfate for interstitial cystitis.
    Palylyk-Colwell E. Issues Emerg Health Technol 2006 May;(84):1-4
    • this review concludes that two non-randomized, uncontrolled pilot studies reported improvements in patient-reported symptoms after the use of chondroitin sulfate for one year
    • the author also concludes that prospective, randomized, head-to-head trials are needed to assess the effectiveness of this technology compared with other IC therapies
  • Antidepressants and cognitive-behavioral therapy for symptom syndromes.
    Jackson JL, O'malley PG, Kroenke K. CNS Spectr 2006;11:212-22
    • this article reviews the randomized controlled trial data for the use of antidepressant and cognitive-behavior therapy for 11 somatic syndromes: irritable bowel syndrome, chronic back pain, headache, fibromyalgia, chronic fatigue syndrome, tinnitus, menopausal symptoms, chronic facial pain, noncardiac chest pain, interstitial cystitis, and chronic pelvic pain
updated 23.11.2007 10:20 © 2006-2018 International Painful Bladder Foundation (IPBF). All rights reserved.